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Abstract
Aims The EMPA‐REG OUTCOME trial demonstrated reductions in cardiovascular (CV) death and heart failure (HF) outcomes
with empagliflozin, a sodium–glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes and established CV disease
over a study period of 3 years. We aimed to investigate the early benefit–risk profile of empagliflozin in patients enrolled in
the EMPA‐REG OUTCOME trial according to HF status at baseline.
Methods and results The effects of treatments on glycated haemoglobin, systolic blood pressure and body weight, and on
the HF endpoints of hospitalization for HF (HHF), HHF or CV death, and HHF or all‐cause mortality were evaluated at 12 weeks,
6 months, and 1 year after randomization. Occurrence of adverse events (AEs) during these time points was also evaluated.
Compared with placebo, empagliflozin lowered glycated haemoglobin, systolic blood pressure, and body weight and rates
of all the HF endpoints, as early as at 12 weeks, regardless of HF status at baseline. Favourable clinical and metabolic effects
were maintained over time. AEs were generally higher in those with HF than without HF; however, compared with placebo,
empagliflozin did not increase risk of developing AEs over the first year of treatment.
Conclusions In the EMPA‐REG OUTCOME trial, the use of empagliflozin led to early and beneficial effects on clinical,
metabolic, and HF outcomes in patients with type 2 diabetes with or without HF at baseline, which were already apparent
within 12 weeks from initiation of treatment. Over the first year of treatment, no safety concern was detected with the
use of empagliflozin.
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Background
Prior to advent of sodium–glucose co‐transporter 2 inhibitors
(SGLT2is), many interventions that improve metabolic
markers of dysglycaemia did not convincingly reduce the risk
of common complications of type 2 diabetes (T2D) such as
macrovascular events or an early death, over several years
of treatment.1,2 Some, such as glitazones, might have actually
caused harm, increasing risk of fluid retention and worsening
heart failure (HF).3 The EMPA‐REG OUTCOME trial showed
that an SGLT2i, empagliflozin, reduced the risk of major car-
diovascular (CV) events by 14%, CV mortality by 38%, and
hospitalization for HF (HHF) by 35% in patients with T2D
and established CV disease.4 These effects were evident early
after treatment initiation and were consistent in those with
and without HF.5 Subsequent trials suggested that other
SGLT2is, such as canagliflozin and dapagliflozin, also reduce
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HHF6,7 in patients with T2D with established CV disease or
with multiple CV risk factors. It is unclear if the rapid and
beneficial effects observed with the use of empagliflozin are
counterbalanced by an increased risk of adverse events,
particularly in the more vulnerable HF population.
Aims
We investigated the early benefits on clinical, metabolic, and
HF outcomes, as well as safety, associated with the use of
empagliflozin in patients with and without HF at baseline
enrolled in the EMPA‐REG OUTCOME trial.
Methods
This is a post hoc analysis of the EMPA‐REG OUTCOME trial.
Briefly, the trial enrolled 7020 participants with T2D and
established CV disease, of whom 706 (10%) had an
investigator‐reported history of HF at baseline based on the
narrow standardized Medical Dictionary for Regulatory
Activities query (SMQ) ‘cardiac failure’ (as defined in Table
1). Patients were randomized in a 1:1:1 ratio to once‐daily
empagliflozin (at a dose of either 10 or 25 mg) or placebo
and followed for a median of 3.1 years. Detailed inclusion
and exclusion criteria and results of primary and secondary
outcomes can be found elsewhere.4 In the current study,
we evaluated the effects of treatments (pooled empagliflozin
arms vs. placebo) on a broad range of outcomes of interest,
including time to first HF outcomes (HHF, HHF or CV death,
and HHF or all‐cause mortality), metabolic [glycated
haemoglobin (HbA1c)] or clinical outcomes [systolic blood
pressure (SBP) and body weight], and the occurrence of
adverse events, at 12 weeks, 6 months, and 1 year after
randomization in people with or without HF at baseline. HF
outcome data were explored descriptively at 12 weeks and
assessed by Cox regression models at 6 months and 1 year,
whereas safety data were explored descriptively. The Cox
model included the interaction of presence of HF at baseline
by treatment to evaluate the treatment effect in patients
with and without HF at baseline separately. The model
further included covariate terms for age, gender, body mass
index, HbA1c, estimated glomerular filtration rate, and
geographical region. The effects on the clinical and metabolic
outcomes (HbA1c, SBP, and body weight) were evaluated
using a mixed effect model repeat measurement model,
which included the baseline of the endpoint (for SBP or body
weight) and baseline HbA1c as linear covariates and their
interaction with visit, estimated glomerular filtration rate
category, geographical region, baseline body mass index
category, and the last week the patient could have had a
measurement of the endpoint and treatment by HF at
baseline by visit interaction as fixed effects. All P‐values
constitute exploratory analyses and are reported without ad-
justment for multiplicity. Statistical analyses were performed
using SAS® Version 9.4.
Results
Baseline characteristics of the study population have been
published previously,4,5 and are summarized in Table 1. Com-
pared with patients without HF, those with HF were older
[mean age (standard deviation): 64.5 (8.8) vs. 63.0 (8.6)
years, P < 0.01], had greater body weight [91.3 (19.4) vs.
85.8 (18.8) kg, P < 0.01] and body mass index [32.1 (5.5) vs.
30.5 (5.2) kg/m2, P < 0.01], and had lower systolic blood
Table 1 Summary of key baseline characteristics
Heart failure
at baselinea
(N ¼ 706)
No heart failure
at baseline
(N ¼ 6314) P‐value
Age, mean
(SD), years
64.5 (8.8) 63.0 (8.6) <0.01
Male, n (%) 495 (70.1) 4521 (71.6) 0.41
Weight, mean
(SD), kg
91.3 (19.4) 85.8 (18.8) <0.01
BMI, mean
(SD), kg/m2
32.1 (5.5) 30.5 (5.2) <0.01
HbA1c, mean
(SD), %
8.07 (0.86) 8.07 (0.85) 0.96
SBP, mean
(SD), mmHg
134 (18) 136 (17) 0.02
DBP, mean
(SD), mmHg
77 (10) 77 (10) 0.61
eGFR, mean (SD),
mL/min/1.73 m2
68.7 (20.4) 74.6 (21.4) <0.01
Therapy
Metformin 446 (63.2) 4747 (75.2) <0.01
Insulin 394 (55.8) 2993 (47.4) <0.01
Sulphonylurea 266 (37.7) 2740 (43.4) <0.01
Dipeptidyl
peptidase‐4
inhibitor
68 (9.6) 728 (11.5) 0.13
Thiazolidinedione 14 (2.0) 285 (4.5) <0.01
Glucagon‐like
peptide‐1 agonist
23 (3.3) 173 (2.7) 0.43
ACE‐I/ARB 612 (86.7) 5054 (80.0) <0.01
Beta‐blockers 559 (79.2) 3995 (63.3) <0.01
MRA 169 (23.9) 272 (4.3) <0.01
Diuretics 506 (71.7) 2529 (40.1) <0.01
Loop diuretics 334 (47.3) 755 (12.0) <0.01
ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin
receptor blocker; BMI, body mass index; DBP, diastolic blood pres-
sure; eGFR, estimated glomerular filtration rate; HbA1c, glycated
haemoglobin; MRA, mineralocorticoid receptor antagonist; SBP,
systolic blood pressure; SD, standard deviation.
aBased on narrow standardized Medical Dictionary for Regulatory
Activities query (SMQ) ‘cardiac failure’, which comprised these
preferred terms: acute pulmonary oedema; cardiac failure; cardiac
failure, acute; cardiac failure, chronic; cardiac failure, congestive;
cardiogenic shock; cardiopulmonary failure; left ventricular failure;
pulmonary oedema; and right ventricular failure.
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pressure [(134 (18) vs 136 (17), P ¼ 0.02), but similar HbA1c
[8.07 (0.86) vs. 8.07 (0.85) %, P ¼ 0.96].
In patients with HF at baseline, the adjusted mean differ-
ences (95% confidence interval) in HbA1c change from base-
line between those randomized to empagliflozin or placebo
at 12 weeks, 6 months, and 1 year after randomization were
0.55 (0.67, 0.44), 0.54 (0.68, 0.40), and 0.53
(0.68, 0.38) %, respectively (P < 0.0001 for all), with sim-
ilar results in those without HF [0.57 (0.60, 0.53), 0.53
(0.58, 0.49), and 0.48 (0.53, 0.43) %, respectively
(P < 0.0001 for all); P for interaction for HF vs. no HF 0.82,
0.94, and 0.54 at 12 weeks, 6 months, and 1 year, respec-
tively]. Compared with placebo, empagliflozin lowered SBP
[adjusted mean differences in the change in SBP from base-
line at 12 weeks, 6 months, and 1 year were 2.43 (4.53,
0.33) (P ¼ 0.023), 2.32 (4.50, 0.14) (P ¼ 0.037), and
2.51 (4.76, 0.26) (P ¼ 0.029) mmHg, respectively, in
those with HF and 4.03 (4.74, 3.32), 4.58 (5.31,
3.84), and 3.48 (4.23, 2.72) mmHg, respectively
(P < 0.0001 for all), in those without HF; P for interaction
0.16, 0.05, and 0.42 at 12 weeks, 6 months, and 1 year, re-
spectively] and body weight at 12 weeks, 6 months, and
1 year, regardless of HF status [adjusted mean differences
in changes in body weight: 1.01 (1.41, 0.60), 1.67
(2.22, 1.12), and 1.96 (2.61, 1.30) kg, respectively
(P < 0.0001 for all), in those with HF and 1.39 (1.53,
1.25), 1.93 (2.12, 1.75), and 1.94 (2.16, 1.72)
kg, respectively (P < 0.0001 for all), in those without HF; P
for interaction for HF vs. no HF 0.08, 0.37, and 0.96 at
12 weeks, 6 months, and 1 year, respectively] (Figure 1).
As early as 12 weeks after randomization, and compared
with those taking placebo, patients treated with
Figure 1 Effects on glycated haemoglobin (HbA1c; top panel), systolic blood pressure (SBP; middle panel), and body weight (lower panel) with
empagliflozin vs. placebo during first year of treatment in patients with (on the left) or without (on the right) heart failure. Error bars represent
95% confidence intervals.
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Table 2 AEs of special interest occurring within 6 months and 1 year after randomization
<6 months <1 year
Patients with heart failure
at baseline
Patients without heart
failure at baseline
Patients with heart failure
at baseline
Patients without heart
failure at baseline
Placebo
(N ¼ 244)
Empagliflozin
(N ¼ 462)
Placebo
(N ¼ 2089)
Empagliflozin
(N ¼ 4225)
Placebo
(N ¼ 244)
Empagliflozin
(N ¼ 462)
Placebo
(N ¼ 2089)
Empagliflozin
(N ¼ 4225)
Any AE, n (%) 176 (72.1) 296 (64.1) 1400 (67.0) 2700 (63.9) 206 (84.4) 363 (78.6) 1694 (81.1) 3246 (76.8)
Any serious AE, n (%) 51 (20.9) 53 (11.5) 268 (12.8) 427 (10.1) 79 (32.4) 105 (22.7) 447 (21.4) 764 (18.1)
Hypoglycaemiaa, n (%) 33 (13.5) 60 (13.0) 301 (14.4) 725 (17.2) 50 (20.5) 76 (16.5) 388 (18.6) 915 (21.7)
Hypoglycaemia requiring
assistance (%)
0 (0) 1 (0.2) 8 (0.4) 17 (0.4) 0 (0) 3 (0.6) 13 (0.6) 27 (0.6)
Acute kidney injuryb, n (%) 1 (0.4) 1 (0.2) 5 (0.2) 6 (0.1) 1 (0.4) 2 (0.4) 7 (0.3) 12 (0.3)
Hyperkalaemiac, n (%) 1 (0.4) 3 (0.6) 11 (0.5) 13 (0.3) 3 (1.2) 4 (0.9) 23 (1.1) 23 (0.5)
Volume depletiond, n (%) 3 (1.2) 11 (2.4) 32 (1.5) 73 (1.7) 10 (4.1) 20 (4.3) 47 (2.2) 111 (2.6)
Hypotensione, n (%) 3 (1.2) 8 (1.7) 28 (1.3) 51 (1.2) 7 (2.9) 14 (3.0) 37 (1.8) 77 (1.8)
AEs, adverse events.
The Medical Dictionary for Regulatory Activities Version 18.0 was used to classify AEs by preferred terms.
aHypoglycaemia defined as any hypoglycaemic event that had a glucose value ≤70 mg/dL or where assistance was required.
bBased on reported AEs of the preferred term in the Medical Dictionary for Regulatory Activities ‘acute kidney injury’.
cBased on the Medical Dictionary for Regulatory Activities preferred terms ‘hyperkalaemia’ and ‘blood potassium increased’.
dBased on eight Medical Dictionary for Regulatory Activities preferred terms ‘blood pressure (BP) ambulatory decreased’, ‘BP decreased’,
‘BP systolic decreased’, ‘dehydration’, ‘hypotension’, ‘hypovolaemia’, ‘orthostatic hypotension’, and ‘syncope’.
eBased on 10 Medical Dictionary for Regulatory Activities preferred terms ‘blood pressure (BP) ambulatory decreased’, ‘BP decreased’, ‘BP
systolic decreased’, ‘BP diastolic decreased’, ‘BP orthostatic decreased’, ‘diastolic hypotension’, ‘hypotension’, ‘mean arterial pressure de-
creased’, ‘orthostatic hypotension’, and ‘orthostatic intolerance’.
Figure 2 Effects on heart failure (HF) outcomes with empagliflozin vs. placebo at 6 months and 1 year by HF status at baseline. CI, confidence interval;
CV, cardiovascular.
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empagliflozin had a lower rate of HHF [0 (0%) vs. 7 (2.9%) and
5 (0.1%) vs. 3 (0.1%) amongst those with and without HF,
respectively], HHF or CV death [1 (0.2%) vs. 10 (4.1%) and 9
(0.2%) vs. 8 (0.4%) in patients with and without HF,
respectively], and HHF or all‐cause mortality [1 (0.2%) vs. 10
(4.1%) and 13 (0.3%) vs. 12 (0.6%) amongst those with and
without HF]. Beneficial effects on HF outcomes were also
observed in the modelled analyses after 6 months and 1 year
in patients with and without HF (Figure 2).
During both 6 month and 1 year time periods, the overall
rates of adverse events and serious adverse events were
numerically higher in those with HF than without HF,
particularly in the placebo arm (Table 2). At 1 year, there
were no differences in hyperkalaemia, volume depletion, or
hypotension between the empagliflozin and placebo
treatment arms for patients with and without HF (Table 2).
Conclusions
In the EMPA‐REG OUTCOME trial, treatment with
empagliflozin led to favourable clinical and metabolic effects
and decreased rates of HF events, in patients with T2D with
or without HF at baseline. These beneficial effects occurred
as early as 12 weeks after initiation of treatment. The use
of empagliflozin was not associated with an increased risk
of adverse events compared with placebo during first year
of treatment.
The mechanisms of the CV benefits associated with
empagliflozin are likely to be multifactorial and largely
independent from an improved glucose control. Previous
post hoc analyses of the EMPA‐REG OUTCOME trial suggested
that CV benefits of empagliflozin were consistent in all
patients, regardless of baseline HbA1c or the magnitude of
its change after 12 weeks of treatment8; conversely, markers
of plasma volume, such as haematocrit and haemoglobin,
were the most important mediators of the reduction in the
risk of CV death.9 Therefore, reduction in cardiac preload
and afterload, caused by an osmotic diuresis, may be one of
the key mechanisms underlying the rapid reduction in SBP,
body weight, and subsequent risk of HF outcomes. As these
effects were also observed in patients without HF, it is
possible that many individuals with T2D and established CV
disease have asymptomatic, or undiagnosed, cardiac
dysfunction and/or preclinical congestion, which might lead
to a greater CV risk.10 However, a reduction in left ventricular
mass,11 or an increase in erythropoietin levels and
erythropoiesis,12 might also explain favourable clinical effects
associated with empagliflozin.
Other hypotheses have been postulated to explain through
which mechanisms empagliflozin exerts its effects and include
a more efficient cardiac metabolism13 and prevention of
cardiac fibrosis.14 In animal models, empagliflozin also
prevented cardiac cytosolic calcium and sodium accumulation
via inhibition of the sodium–hydrogen exchanger, processes
that could contribute to T2D and development of HF, and
improved mitochondrial function.15
Recently, McMurray and colleagues reported that an
SGLT2i, dapagliflozin, was superior to placebo in reducing risk
of CV death and worsening HF in patients with HF and
reduced left ventricular ejection fraction (HFrEF), regardless
of T2D,16 without increasing the frequency of adverse
events related to volume depletion, renal dysfunction, and
hypoglycaemia. This further supports the hypothesis that
control of glycaemia is not the key mechanism by which
SGLT2is exert their beneficial effects in people with T2D at
high CV risk.
Patients with HF are more vulnerable to developing
adverse events, and it is therefore reassuring that the
overall frequency of adverse events and serious adverse
events early after treatment initiation was numerically lower
in the empagliflozin arm. We observed no increase in acute
kidney injury in those with HF as compared with those
without HF treated in the empagliflozin arm. This is
supported by another recent sub‐analysis of EMPA‐REG
OUTCOME focusing on renal outcomes, which showed that
empagliflozin reduced the risk of incident or worsening
nephropathy in those with and without HF during the entire
length of the study.17
The current analysis has some limitations. Firstly, this
analysis was developed post hoc. Secondly, levels of
circulating natriuretic peptides or left ventricular ejection
fraction were not captured at baseline, and we could not
differentiate amongst different HF phenotypes. Furthermore,
as expected for the population enrolled in EMPA‐REG
OUTCOME trial, rates of HF events were low during the first
year of follow‐up. Lastly, as in most clinical trials, adverse
events were not adjudicated but coded via Medical
Dictionary for Regulatory Activities terms.
Large ongoing trials of empagliflozin [the EMPEROR
Program (NCT03057951 and NCT03057977) and the
EMPERIAL Trials (NCT03448406 and NCT03448419)],18,19
along with more detailed analyses from DAPA‐HF trial,16 will
provide additional evidence for the effect and safety of
SGLT2is in patients with HF and either reduced or preserved
ejection fraction, regardless of T2D, and clarify further their
complex mechanisms of action.
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